PUBLICATION

Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

Authors
Kamel, S.M., van Opbergen, C.J.M., Koopman, C.D., Verkerk, A.O., Boukens, B.J.D., de Jonge, B., Onderwater, Y.L., van Alebeek, E., Chocron, S., Polidoro Pontalti, C., Weuring, W.J., Vos, M.A., de Boer, T.P., van Veen, T.A.B., Bakkers, J.
ID
ZDB-PUB-211214-29
Date
2021
Source
Nature communications   12: 7151 (Journal)
Registered Authors
Bakkers, Jeroen, Chocron, Sonja
Keywords
none
MeSH Terms
  • Animals
  • Calcium/metabolism*
  • Calcium-Binding Proteins/genetics*
  • Calcium-Binding Proteins/metabolism
  • Cardiomyopathy, Dilated/genetics*
  • Cardiomyopathy, Dilated/metabolism
  • Cardiomyopathy, Dilated/physiopathology
  • Disease Models, Animal
  • Echocardiography
  • Etiocholanolone/administration & dosage
  • Etiocholanolone/analogs & derivatives*
  • Female
  • Gene Knock-In Techniques
  • Humans
  • Male
  • Myocardial Contraction
  • Myocardium/metabolism
  • Sequence Deletion
  • Zebrafish/genetics
  • Zebrafish/metabolism*
PubMed
34887420 Full text @ Nat. Commun.
Abstract
The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca2+ level, slower Ca2+ transient decay and longer Ca2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping